N. Morrell

发表

Fibrinogen Aα Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension

F. Dudbridge, J. Eikenboom, C. Treacy, 2008, European Respiratory Journal.

Full Title: Fibrinogen AαThr312Ala polymorphism is associated with Chronic Thromboembolic Pulmonary Hypertension Short title: Fibrinogen AαThr312Ala in CTEPH Authors

F. Dudbridge, J. Eikenboom, C. Treacy, 2007 .

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

H. Ghofrani, F. Grimminger, R. Barst, 2010, American journal of respiratory and critical care medicine.

Long Term Use Of Imatinib In Patients With Severe Pulmonary Arterial Hypertension

H. Ghofrani, R. Barst, M. Hoeper, 2010, ATS 2010.

Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES)

R. Barst, A. Peacock, G. Simonneau, 2011 .

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

H. Ghofrani, F. Grimminger, R. Barst, 2013, Circulation.

In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma

N. Morrell, H. Jones, N. Morrell, 2003, European Respiratory Journal.

Familial spontaneous pneumothorax and lung cysts due to a Folliculin exon 10 mutation

N. Morrell, A. Tasker, S. Sundaram, 2009, European Respiratory Journal.

The fibrocyte in pulmonary hypertension: we seek him here, we seek him there

N. Morrell, M. Toshner, N. Morrell, 2012, European Respiratory Journal.

Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension

W. Seeger, N. Weissmann, R. Schermuly, 2010, European Respiratory Journal.

Tumour necrosis factor-α gene promoter polymorphism in chronic obstructive pulmonary disease

N. Pride, N. Morrell, M. Higham, 2000 .

Relationship between impaired BMP signalling and clinical risk factors at early-stage vascular injury in the preterm infant

T. Desai, R. Morty, P. Ahnert, 2022, Thorax.

ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders

N. Morrell, A. Aldashev, M. Mirrakhimov, 1999, The Lancet.

Single-cell RNA sequencing profiling of mouse endothelial cells in response to pulmonary arterial hypertension

P. Carmeliet, M. Brittan, R. Lafyatis, 2021, Cardiovascular research.

Right ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary artery: a pressure-volume study using the conductance catheter.

A. Priest, P. White, R. Axell, 2014, Journal of applied physiology.

Screening asymptomatic BMPR2 mutation carriers: a new frontier for pulmonary hypertension physicians?

N. Morrell, 2021, European Respiratory Journal.

miR-1-5p targets TGF-βR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension

S. Wort, N. Morrell, A. Crosby, 2020, PloS one.

Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease.

N. Pride, N. Morrell, M. Higham, 2000, The European respiratory journal.

Imatinib Improves Exercise Capacity and Hemodynamics at 24 Weeks as Add-on Therapy in Symptomatic Pulmonary Arterial Hypertension Patients: The IMPRES Study

H. Ghofrani, R. Barst, A. Frost, 2011 .

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective

M. Yacoub, A. Shah, S. Pullamsetti, 2021, Nature Reviews Cardiology.

Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland

G. MacGowan, P. Corris, M. Gatzoulis, 2008, Heart.

Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis

J. Rajadas, K. Youker, Wenchao Sun, 2017, British journal of pharmacology.

Non-generalizability of biomarkers for mortality in SARS-CoV-2: a meta-analyses series

R. Samworth, Felipe Soares, N. Morrell, 2022, medRxiv.

The integrated stress response in pulmonary disease

S. Marciniak, N. Morrell, G. Emanuelli, 2020, European Respiratory Review.

Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD.

P. Nihoyannopoulos, N. Morrell, D. Dawson, 2001, The European respiratory journal.

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.

Hyuk-Jae Chang, H. Ghofrani, R. Barst, 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

miR‐322‐5p targets IGF‐1 and is suppressed in the heart of rats with pulmonary hypertension

S. Wort, N. Morrell, A. Crosby, 2018, FEBS open bio.

Future Directions: An Expert Panel Explores the Challenge of Halting Progression and Reversing the Pathology of PAH

S. Rich, N. Voelkel, S. Gaine, 2003 .

Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats

W. Seeger, S. Pullamsetti, N. Weissmann, 2010, European Respiratory Journal.

Ventriculo‐arterial coupling detects occult RV dysfunction in chronic thromboembolic pulmonary vascular disease

A. Priest, P. White, R. Axell, 2017, Physiological reports.

IMATINIB MESYLATE TREATMENT FOR SEVERE PULMONARY ARTERIAL HYPERTENSION: A PROPOSED PHASE III 24-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL

R. Barst, M. Hoeper, H. Olschewski, 2009 .

Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension.

F. Dudbridge, J. Eikenboom, C. Treacy, 2008, The European respiratory journal.

Imatinib Safety And Efficacy: Interim Analysis Of IMPRES Extension Study In Patients With Pulmonary Arterial Hypertension

H. Ghofrani, R. Barst, H. Klose, 2012, ATS 2012.

CVR-2020-1310 Single-cell RNA-seq profiling of mouse endothelial cells in response to pulmonary arterial hypertension

P. Carmeliet, M. Brittan, J. Rodor, 2021 .